Home › Trials › NCT06512974
Clinical trial Recruiting at 3 sites Interventional Ages 11 to 17

NeuroTrainer VR cognitive program to improve academic focus

Official title: A Feasibility and Efficacy Study of NeuroTrainer Cognitive Training in Students With and Without Attention-Related Difficulties

Run by NeuroTrainer · NCT06512974 · Data updated 2026-11-12

This project will test whether NeuroTrainer's VR-based cognitive and physical training can help 11–17 year-olds with or without ADHD improve attention and executive control.

Quick facts

Study typeInterventional
Ages11 Years to 17 Years
SexAll
Enrollment155 (estimated)
SponsorNeuroTrainer
Industry-sponsored
Locations3 sites (Marquette, Michigan and 2 other locations)
StatusRecruiting
StartedSeptember 1, 2024
Main results expectedFebruary 28, 2026
Study endsFebruary 28, 2026
Registry record updatedJune 19, 2025
Trial IDNCT06512974 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are students aged 11–17 (estimated IQ ≥ 80) who have any presentation of ADHD or are school-aged participants without attention-related difficulties and who do not meet exclusion criteria.

Probably not a fit

Patients with active suicidality, psychotic disorders, severe depression, significant hearing or visual impairment, or estimated IQ below 80 (and those outside the 11–17 age range) are excluded and unlikely to benefit from this program.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares NeuroTrainer — a virtual-reality program that combines physical activity with adaptive cognitive tasks — to a control condition in adolescents. Participants aged 11–17, both with and without ADHD, complete repeated VR training sessions that maximize time at performance thresholds and vary task demands. Researchers will measure changes in attentional and executive-control tasks, whether the program engages the hypothesized cognitive targets of inattention, and whether any gains transfer to academic behaviors. Outcomes will be determined by pre- and post-intervention testing and comparison to the control group.

Why it matters

Potential benefit: If successful, NeuroTrainer could improve attention, executive control, and classroom performance for adolescents and offer a non-drug option to complement existing treatments.

How similar studies have gone: Prior cognitive-training trials for ADHD have shown mixed results, and while pilot VR and physically-engaged cognitive programs are promising, strong evidence of consistent academic transfer remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Diagnostic criteria met ADHD for any ADHD presentation type, with severity ratings of subthreshold, moderate or severe
* Estimated IQ of 80 or greater
* Between 11-17 years of age

Exclusion Criteria:

* Presence of suicidality
* Presence of psychotic disorders
* Visual or hearing impairment
* Presence of severe depression

Where it's running

  • Marquette Senior High School
    Marquette, Michigan, United States     Recruiting
  • Westside High School
    Omaha, Nebraska, United States     Recruiting
  • One City Schools
    Madison, Wisconsin, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
ADHD - Combined Type 6ADHD Predominantly Inattentive Type 3ADHD, Predominantly Hyperactive - Impulsive 3
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.